WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology company that develops
anticancer therapeutics using its Targeted Antibody Payload (TAP)
technology and antibody expertise, today announced that Daniel Junius,
President and CEO, will present at the upcoming Oppenheimer 23rd
Annual Healthcare Conference in New York. The presentation is scheduled
for 10:00 am ET on December 13, 2012.
The webcast of this presentation can be accessed live through the
"Investor Information" section of the Company's website, www.immunogen.com;
a replay of the presentation will be available at the same location for
one week.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using its TAP
technology together with the Company's expertise in monoclonal
antibodies and tumor biology. A TAP compound uses a tumor-targeting
monoclonal antibody to deliver one of ImmunoGen's purpose-developed
cancer-killing agents specifically to tumor cells. Ten TAP compounds are
now in clinical testing, of which three are wholly owned by the Company.
Marketing applications for trastuzumab emtansine (T-DM1), the most
advanced compound using ImmunoGen's TAP technology, are under review in
the US and Europe. Roche is developing this compound globally under an
agreement between ImmunoGen and Genentech, a member of the Roche Group.
More information about ImmunoGen can be found at www.immunogen.com.
For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive
Director, Investor Relations and Corporate Communications
info@immunogen.com
or
For
Media:
The Yates Network
Barbara Yates, 781-258-6153
Source: ImmunoGen, Inc.
News Provided by Acquire Media